NorthWest Biotherapeutics Inc (NWBO)

[abeta]

05 March 2024

A meeting was held between NICE and the company in early-February regarding next steps for the appraisal of DCVax-L for treating glioblastoma, and more information will be available in due course. NICE will continue liaising with the company and monitoring timelines.

https://www.nice.org.uk/guidance/indevelopment/gid-ta10143

=================================================
August 2023

Hallmarks of the Tumour Microenvironment of Gliomas and Its Interaction with Emerging Immunotherapy Modalities

Therapeutic cancer vaccines: DCs derived from the patient’s peripheral blood monocytes are pulsed ex vivo with tumour lysate and are trained to recognise T cells. The educated T cells recognise tumour antigens and initiate cell lysis. DCVax-L is used to treat brain tumours in combination with ICIs. Dendritic cells (DCs), T cell receptor (TCR), cytotoxic T lymphocytes (CTLs), major histocompatibility complex (MHC). Created with BioRender.com.

In 2022, a study found that adding autologous tumour lysate-loaded DC vaccine (DCVax-L) to SOC resulted in a significant extension of OS for patients with both newly diagnosed and recurrent glioblastoma, with an even greater relative survival benefit observed among patients who would have generally fared worse with SOC [24]. Whilst DCVax-L is not yet approved by the Food and Drug Administration (FDA) in the United States or the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, it has recently been made available for private use in the UK (Northwest Biotherapeutics 2017) [57], and the National Institutes of Health and Care Excellence (NICE) are conducting a technology appraisal of the clinical and cost effectiveness of DCVax-L for newly diagnosed glioblastoma [58].

https://www.mdpi.com/1422-0067/24/17/13215


The duality of CXCR3 in glioblastoma: unveiling autocrine and paracrine mechanisms for novel therapeutic approaches
12/2023
https://www.nature.com/articles/s41419-023-06354-2